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Abstract
Rationale: Estimating the impact of ventilator-associated
pneumonia (VAP) from routinely collected intensive care unit
(ICU) data is methodologically challenging.
Objectives: We aim to replicate earlier findings of limited VAP-
attributable ICU mortality in an independent cohort. By refining
statistical analyses, we gradually tackle different sources of bias.
Methods: Records of 2,720 adult patients admitted to Ghent
University Hospital ICUs (2013–2017) and receiving mechanical
ventilation within 48 hours after admission were extracted from
linked Intensive Care Information System and Computer-
based Surveillance and Alerting of Nosocomial Infections,
Antimicrobial Resistance, and Antibiotic Consumption in the
ICU databases. The VAP-attributable fraction of ICU mortality
was estimated using a competing risk analysis that is restricted to
VAP-free patients (approach 1), accounts for VAP onset by
treating it as either a competing (approach 2) or censoring event
(approach 3), or additionally adjusts for time-dependent
confounding via inverse probability weighting (approach 4).
Results: A total of 210 patients (7.7%) acquired VAP. Based on
benchmark approach 4, we estimated that (compared with current
preventive measures) hypothetical eradication of VAP would lead to
a relative ICUmortality reduction of 1.7% (95% confidence interval,
21.3 to 4.6) by Day 10 and of 3.6% (95% confidence interval, 0.7 to
6.5) by Day 60. Approaches 1–3 produced estimates ranging from
20.7% to 2.5% by Day 10 and from 5.2% to 5.5% by Day 60.
Conclusions: In line with previous studies using appropriate
methodology, we found limited VAP-attributable ICU mortality
given current state-of-the-art VAP prevention measures. Our study
illustrates that inappropriate accounting of the time dependency
of exposure and confounding of its effects may misleadingly
suggest protective effects of early-onset VAP and systematically
overestimate attributable mortality.
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Hospital-acquired infections (HAIs) form a
major public health problem in developed
countries, as they are associated with
increased morbidity, mortality, and
health-related costs (1–3). Given their
critical illness and exposure to invasive
treatments, intensive care unit (ICU)
patients are particularly prone to acquiring
HAIs, especially ventilator-associated
pneumonia (VAP).
Appropriate quantification of the
impact and burden of unprevented VAP is
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imperative to understanding its severity and
the importance of additional preventive
measures and timely treatment. Although its
occurrence is reported to be associated with
increased ICU mortality, the well-known
mantra “correlation does not imply
causation” dictates that a considerable
number of intubated patients die with,
but not necessarily from, VAP. Estimation
of the causal impact of HAIs, however,
remains subtle and controversial because
such assessments are based on either
observational data or randomized trials with
varying levels of preventive effectiveness
(4). Given the multitude of potential sources
of variation, past observational studies
produced highly variable findings, with
excess risk estimates ranging from 0% to
50% (5).
Multistate model (MSM) approaches
for estimating mortality and prolonged stay
due to HAIs have been widely advocated
in recent years, as they aid in avoiding
common types of bias (5–7). Their focus
on a specific effect measure, the time-
dependent population-attributable fraction
(PAF), may moreover reduce variability in
findings because of various definitions of
excess risk. Even so, widely used MSM
approaches (8) produce results that cannot
be causally interpreted, even in the absence
of confounding (9, 10). Moreover, MSM
approaches are ill equipped to tackle bias
due to group imbalances in prognostic
factors that may accrue over the course
of time. They may therefore misinform
clinical practice. This latter shortcoming,
although repeatedly highlighted in
the literature (5, 11, 12), remains
underappreciated.
The aim of this article is twofold. First,
we aim to replicate earlier findings from
Bekaert and colleagues (13), who provided
the first and (to our knowledge) only study
to appropriately address time-dependent
confounding in the estimation of VAP-
attributable ICU mortality. We assess
whether their findings of limited VAP-
attributable ICU mortality, which are based
on the French multicenter Outcomerea
database (n= 4,479) (1997–2008), generalize
to an independent cohort of 2,720
mechanically ventilated patients. To
maximally reduce bias and ensure between-
study comparability, we use identical
estimation approaches for causal inference.
Second, we illustrate the importance of
appropriately accounting for the time-
dependent nature of events under study and
of their confounding factors by comparing
results with those produced by MSM
approaches. In doing so, we gradually
refine our analysis to demonstrate, in each
subsequent step, how different types of bias
can be eliminated or reduced.
Methods
Study Population
VAP-attributable ICU mortality was
estimated on the basis of records of a
cohort of adult patients (aged 18 or older)
admitted to the Ghent University Hospital
(medical and surgical) ICUs between
January 2013 and November 2017, who
stayed at the ICU for at least 48 hours and
received mechanical ventilation within 48
hours after admission. In the case of ICU
readmissions, only the first episode was
included.
Data Collection
Admission characteristics were extracted
from the Intensive Care Information System
database (GE Healthcare Centricity Critical
Care) and consisted of demographic data
(sex, age, and weight), admission category
(medicine, emergency surgery, or scheduled
surgery), and severity of illness and
comorbidities as captured by the APACHE
(Acute Physiology and Chronic Health
Evaluation) II score and the updated
Charlson comorbidity index (14),
respectively. In addition, ICU admission
and discharge dates, ICU survival, and data
on daily interventions and treatments were
extracted, including enteral feeding,
corticosteroids (.0.5 mg/kg), mechanical
ventilation, use of vasoactive agents,
hemodialysis, tracheotomy tube, and
treatment limitation decisions (codes 0–4).
Measurements of daily disease severity
and organ function, as captured by the
Sequential Organ Failure Assessment score,
were extracted from the Computer-based
Surveillance and Alerting of Nosocomial
Infections, Antimicrobial Resistance, and
Antibiotic Consumption in the ICU
(COSARA) (15–17) database.
Following De Bus and colleagues (18),
VAP was defined as “hospital-acquired
pneumonia diagnosed in patients under
mechanical ventilation for 48 hours or
longer, or in patients who had been
extubated for less than 48 hours after
mechanical ventilation for at least 2 days” to
exclude community-acquired pneumonia or
other types of hospital-acquired pneumonia
unrelated to mechanical ventilation. Daily
indicators of the acquisition of VAP and
other infections (fungal infections and
bacterial infections, including abdominal,
catheter-related, respiratory, and urinary tract
infections), and administered antibiotic
treatments were extracted from the COSARA
database. A more detailed list of extracted
variables, their definitions, and (re)coding are
included in the online supplement.
The Ghent University Hospital Ethics
Committee approved the study (registration
number B670201732106) and waived
informed consent because all analyses
were performed retrospectively on
pseudonymized records. Unique patient and
ICU admission identifiers allowed us to link
the extracted records.
Statistical Analysis
In this article, we focus on estimation of the
time-dependent PAF of ICU mortality due
to VAP, which expresses the proportion of
preventable death cases in the ICU in the
absence of VAP as a function of time since
admission. This (inherently causal) effect
measure involves a comparison of the
observed cumulative incidence of ICU
death, which can readily be estimated
using a standard competing risk (CR)
analysis (that treats ICU discharge as a
competing event), with the nonobservable
counterfactual cumulative incidence of ICU
death that would have been observed if,
counter to the fact, VAP had been avoided in
all considered patients. Because of its
hypothetical nature, the estimation of this
second quantity is more challenging. We
revisit and compare four proposed
approaches for estimating the time-
dependent PAF (within the first 60 d after
ICU admission), which differ only in the
estimation of this counterfactual (VAP-free)
cumulative incidence. Each of these
approaches apportions weights to VAP-free
events that are inversely proportional to the
amount of selection of VAP-free patients in
the analysis to “reconstruct” the original
cohort in the absence of VAP. However,
their respective weighting schemes differ in
terms of how well they respect the temporal
ordering of events and take into account
differential selection of VAP-free patients
over time. In a methodological companion
paper (19), we illustrate how each approach
involves a refinement with respect to
another, thereby enabling us to gradually
tackle and assess different sources of bias.
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In the discussion (and in the online
supplement), we provide more intuition into
these refinements.
Approach 1 approximates this quantity
by the cumulative incidence of ICU death in
patients who remained VAP-free until death
or discharge, as estimated by a standard
CR analysis (using the Aalen-Johansen
estimator), treating ICU discharge as a
competing event. This approach ignores
VAP onset time or, equivalently, VAP-free
patient-time of infected patients.
Approach 2 is based on a CR analysis
that treats VAP-free ICU discharge and VAP
onset as competing events for VAP-free ICU
death. The counterfactual cumulative
incidence of ICU death is estimated as a
function of the respective cumulative
incidences of these competing events that
takes into account VAP onset. This approach
corresponds with estimation of the PAF by a
particular MSM (i.e., the progressive disability
model), and was originally proposed by
Schumacher and colleagues (8).
Approach 3, also based on a CR analysis,
accounts for VAP onset by treating it as a
censoring event rather than a competing event
for both ICUdischarge and death. By censoring
infected patients as soon as they acquire VAP,
this approach aims to recover the cumulative
incidence of ICU death had all patients
remained without VAP. This alternativeMSM-
based approach (20) was originally proposed in
another setting and corresponds with an
inverse probability (IP) of censoring weighted
Aalen-Johansen estimator of VAP-free ICU
mortality, which weighs each VAP-free event
by the probability of a patient having remained
VAP-free while hospitalized (21).
Approach 4 is an extension of approach
3 in which informative censoring of infected
patients (or, equivalently, time-dependent
confounding of the effect of VAP) is
accounted for by incorporating patient
(covariate) history into the calculation of
the IP weights. This approach is identical
to previously suggested causal inference
techniques based on IP weighting (13, 22–25)
and involves a more elaborate modeling
component (because of adjustment for time-
dependent covariates). In particular, a Cox
proportional hazards model was fitted for the
daily probability of acquiring VAP in function
of the available covariate history, including
admission characteristics and time-dependent
factors as listed in DATA COLLECTION. For each
VAP-free patient-day at the ICU, weights were
calculated from the fitted probabilities from
the final Cox model. These time-dependent,
patient-specific weights express the reciprocal
of the probability of a patient having remained
VAP-free while hospitalized and the patient’s
observed covariate profile up to that day
(for more details on causal and modeling
assumptions, the set of adjusted covariates,
obtained balance across these covariates, and
the distribution of the IP weights, see online
supplement and Figures E1–E5).
We used nonparametric bootstrapping
based on 1,000 samples to calculate
percentile-based 95% confidence intervals
(CIs) for the time-dependent PAF as
estimated by each of the four approaches.
All analyses were conducted in R (26)
(version 4.0.2) using the ipw (27) and
survival (28) R packages.
The STROBE (strengthening the
reporting of observational studies in
epidemiology) (29) and RECORD (the
reporting of studies conducted using
observational routinely-collected health
data) (30) guidelines were followed.
Results
Descriptives
For 2,729 patients, the first ICU episode that
fulfilled the inclusion criteria was included
(see flow diagram in Figure 1). Nine episodes
were excluded from final analyses because
either ICU survival (one episode) or
APACHE II score (eight episodes) was
missing. During the 32,526 patient-days of
follow-up in the remaining 2,720 patients,
210 patients (7.7%) developed VAP,
resulting in 29,091 VAP-free patient-days
and 3,471 VAP-infected patient-days (note
that, for the purpose of this analysis, every
patient-day after VAP onset is considered a
VAP-infected patient-day). Half of patients
infected with VAP were diagnosed with
VAP within 5 days of admission. Patients
who acquired VAP had a median ICU
stay of 21 days and received mechanical
ventilation for a median duration of 15 days.
In contrast, patients who did not acquire
VAP had a median ICU stay of only 7
days and received mechanical ventilation
for a median duration of 3 days. Patient
characteristics on admission and crude
mortality rates are summarized in Table 1.
VAP-Attributable Fraction of
ICU Mortality
Figure 2 and Table 2 provide a
comprehensive comparison of the results
obtained from the different estimation
approaches under study. The observed 10-
day, 30-day, and 60-day ICU mortality risk
in mechanically ventilated patients was
12.5% (340 ICU deaths of 2,720 patients),
18.9% (513/2720), and 19.9% (540/2720),
respectively (t-day ICU mortality risk
corresponds with the proportion of all
admitted patients who died in the ICU
within t days after admission).
Among patients who did not acquire
VAP by the end of follow-up (approach 1),
the 10-day ICU mortality risk was 12.6%
(316/2510). Extrapolated to the original
population, it was estimated that if all patients
had remained without VAP, approximately
342 patients would have died in the ICU by
Day 10. In other words, approach 1 estimated
an excess of two deaths by Day 10 in the
absence of VAP (PAF=20.7%; 95% CI,
23.6% to 0.2%). In contrast, it was estimated
that 23 ICUdeaths could have been prevented
by Day 30 (PAF=4.5%; 95% CI, 1.8–7.4%)
and approximately 30 deaths could have
been prevented by Day 60 (PAF=5.5%; 95%
CI, 2.9–8.2%) if all patients had remained
without VAP.
Approach 2 produced a highly similar
estimate to approach 1 at Day 30 and an
identical one at Day 60 (because no patients
acquired VAP after Day 60), but a positive
estimate of the counterfactual risk at Day 10.
Among patients who remained without
VAP (at least) up to Day 10, the 10-day ICU
mortality risk was 12.3% (316/2560). This
approach thus suggests that had all patients
remained without VAP (at least) up to Day
10, nearly 336 would have died at the ICU by
Day 10, corresponding with four prevented
deaths by Day 10 (PAF= 1.3%; 95% CI,
21.5% to 3.7%).
Approach 3 estimated that almost eight
deaths could have been prevented by Day 10
(PAF= 2.5; 95% CI,20.3% to 5.1%). At Days
30 and 60, approach 3 produced similar
estimates to those of approaches 1 and 2.
Finally, according to approach 4, the 10-
day, 30-day, and 60-day ICU mortality risks
had all patients remained without VAP were
estimated to be 12.3%, 18.2%, and 19.1%,
respectively. These estimated risks correspond
with considerably lower estimates of the
number of preventable cases at longer follow-
up as compared with the other approaches:
6.2 by Day 10 (PAF=1.8%; 95%CI,21.1% to
4.8%), 16.8 by Day 30 (PAF=3.3%; 95% CI,
0.2–6.3%), and 19.9 by Day 60 (PAF=3.7%;
95% CI, 0.8–6.6%).
In sum, the favored benchmark
approach 4 demonstrates that ICUmortality
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15,943 ICU episodes
(Jan 1st 2013–Nov 8th 2017) 8,752 episodes of <48 hours excluded
7,191 ICU episodes of 48 hours
3,918 episodes without mechanical
ventilation excluded
285 readmissions (with mechanical
ventilation) excluded
2,988 first ICU episodes of 48 hours
with mechanical ventilation in the study
period
18 admissions of patients <18 years
old
2,970 episodes in patients 18 years old
40 episodes in which mechanical
ventilation was initiated more than 
48 hrs after admission excluded
1 episode with incorrect admission time
excluded
2,729 episodes in which mechanical
ventilation was initiated within first 48 hrs 1 episode with unknown ICU mortality
status excluded
2,728 episodes with recorded ICU mortality
status
8 episodes with unknown APACHE II
score at admission excluded












Figure 1. Study flow diagram. APACHE=Acute Physiology and Chronic Health Evaluation; ICU= intensive care unit; VAP= ventilator-associated
pneumonia.
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attributable to VAP is very limited
(approximately 3–4% by Day 60). Shortly
after ICU admission (within the first 2 wk),
approach 1 indicates a modest but
nonnegligible protective effect of VAP,
which is not corroborated by more
refined analyses (approaches 2–4). When
considering larger time windows, approach
4 indicates that the attributable ICU
mortality due to VAP may be even smaller
compared with estimates obtained from less
refined analyses (approaches 1–3).
Discussion
In this study, we aimed to replicate earlier
findings of limited VAP-attributable ICU
mortality (13) and, in doing so, illustrate the
importance of appropriately accounting for
the time-dependent nature of the events
under study and their confounding factors.
Main Findings
We estimated that by Day 30, 3.3% of deaths
in ventilated patients could have been
avoided by successful VAP prevention. By
Day 60, the proportion of preventable cases
increased to 3.7%. Although largely in line
with the modest impact reported by Bekaert
and colleagues (13) (4.4% on Day 30 and
5.9% on Day 60), we found an even more
limited impact. Between-study variability in
estimates may be related to a host of factors,
such as differences in the patient case mix,
diagnostic procedures and definitions,
characteristics of infection, timeliness and
appropriateness of treatment, application of
different (and often suboptimal) statistical
methods, and use of various definitions of
excess risk (5, 13). In keeping with Bekaert
and colleagues (13), we have chosen to focus
on the PAF because of its intuitively
appealing interpretation and its central role
as a target of inference of predominant
MSM-based approaches (8). Unlike other
effect measures, such as the absolute risk
reduction, it implicitly captures VAP
incidence because not only lower incidences
of ICU mortality but also higher incidences
of infection translate into larger PAFs. A
differential incidence ratio may explain
discrepancies between our findings, based on a
cohort in which 7.7% of patients acquired








Sex, M, n (%) 146 (69.5) 1,569 (62.5) 1,715 (63.1)
Age, mean (SD), yr 56.1 (16.7) 60.5 (15.7) 60.2 (15.9)
ICU length of stay, median (Q1–Q3), d 21 (12–31) 7 (5–13) 8 (5–15)
Ventilation, median (Q1–Q3), d 15 (9–23) 3 (2–8) 4 (2–9)
APACHE II score, mean (SD) 27.1 (6.8) 27.1 (6.7) 27.1 (6.7)
SOFA score on admission, mean (SD) 9.5 (3.7) 9.1 (3.7) 9.1 (3.7)
Respiratory, mean (SD) 2.2 (1.3) 2.1 (1.2) 2.1 (1.2)
Coagulation, mean (SD) 0.7 (1.1) 0.6 (1.0) 0.6 (1.0)
Liver, mean (SD) 0.3 (0.7) 0.4 (0.9) 0.4 (0.9)
Cardio, mean (SD) 3.1 (1.5) 2.7 (1.6) 2.8 (1.6)
Central nervous system, mean (SD) 2.6 (1.8) 2.8 (1.7) 2.8 (1.7)
Renal, mean (SD) 0.5 (0.9) 0.5 (0.9) 0.5 (0.9)
Admission category, n (%)
Medicine 70 (33.3) 956 (38.1) 1,026 (37.7)
Emergency surgery 111 (52.9) 1,023 (40.8) 1,134 (41.7)
Scheduled surgery 29 (13.8) 531 (21.2) 560 (20.6)
Charlson comorbidity index (updated), mean (SD) 1.2 (1.7) 2.1 (2.4) 2.0 (2.3)
Myocardial infarction, n (%) 9 (4.3) 126 (5.0) 135 (5.0)
Congestive heart failure, n (%) 33 (15.7) 486 (19.4) 519 (19.1)
Peripheral vascular disease, n (%) 28 (13.3) 324 (12.9) 352 (12.9)
Cerebrovascular disease, n (%) 12 (5.7) 141 (5.6) 153 (5.6)
Dementia, n (%) 1 (0.5) 30 (1.2) 31 (1.1)
Chronic pulmonary disease, n (%) 26 (12.4) 373 (14.9) 399 (14.7)
Mild liver disease, n (%) 8 (3.8) 38 (1.5) 46 (1.7)
Diabetes without chronic complications, n (%) 20 (9.5) 364 (14.5) 384 (14.1)
Diabetes with chronic complications, n (%) 5 (2.4) 54 (2.2) 59 (2.2)
Hemiplegia or paraplegia, n (%) 5 (2.4) 67 (2.7) 72 (2.6)
Renal disease, n (%) 21 (10.0) 423 (16.9) 444 (16.3)
Anymalignancy, incl leukemia and lymphoma, n (%) 23 (11.0) 418 (16.7) 441 (16.2)
Moderate or severe liver disease, n (%) 10 (4.8) 259 (10.3) 269 (9.9)
Metastatic solid tumor, n (%) 2 (1.0) 187 (7.5) 189 (6.9)
AIDS/HIV, n (%) 3 (1.4) 13 (0.5) 16 (0.6)
Crude mortality rates
30-d ICU mortality, n (%) 60 (28.6) 451 (18.0) 511 (18.8)
60-d ICU mortality, n (%) 69 (32.9) 470 (18.7) 539 (19.8)
Global ICU mortality, n (%) 69 (32.9) 473 (18.8) 542 (19.9)
Definition of abbreviations: AIDS=acquired immunodeficiency syndrome; APACHE=Acute Physiology and Chronic Health Evaluation; HIV= human
immunodeficiency virus; ICU= intensive care unit; incl = including; Q1= first quartile or 25th percentile; Q3= third quartile or 75th percentile; SD= standard
deviation; SOFA=Sequential Organ Failure Assessment; VAP= ventilator-associated pneumonia.
ORIGINAL RESEARCH
834 AnnalsATS Volume 18 Number 5| May 2021
VAP and 19.9% died in the ICU by Day 60
(incidence ratio = 0.39), and those of Bekaert
and colleagues (13), who reported incidences
of 15.3% and 25.6% respectively (incidence
ratio = 0.60). Remarkably, despite lower
incidences, our cohort had worse prognosis at
ICU admission (Simplified Acute Physiology
Score II interquartile range, 59–80 versus 28–
53). Our smaller estimates may also, in part,
reflect a smaller excess risk of death in patients
with a poorer prognosis (13, 31, 32).
Comparison with Findings from
Conventional Statistical Approaches
Our focus on the time-dependent PAF
facilitated both between-study comparisons
and within-study comparisons of alternative
estimation approaches targeting the same
effect measure. Together with a recent study
by von Cube and colleagues (9), our study
is among the first to compare different
MSM approaches for estimating the time-
dependent PAF of ICUmortality due to VAP.
Although their comparison did not include an
analysis that adjusts for time-dependent
confounding (approach 4) or a naive CR
analysis (approach 1), we chose to also
include these for two reasons. First, we believe
that proper adjustment for available time-
dependent factors may considerably reduce
confounding bias and therefore produce the
most reliable benchmark. Second, under
certain assumptions, the PAF can be
interpreted as the relative mortality reduction
in an RCT that randomly assigns eligible
patients to receive either a fully effective
bundle of preventive measures or standard of
care (for more details, see the online
supplement). A recent characterization
reveals that the compared approaches can be
organized hierarchically with respect to how
well they emulate this hypothetical prevention
trial using observational data (19). To the best
of our knowledge, this is the first study to
directly compare these four approaches in a
hierarchical fashion.
Approach 1 compares the original
population with patients who remained VAP-
free until death or discharge. This comparison
is known to produce immortal time bias
because unlike patients who eventually
acquired VAP, these patients may not have
survived long enough to acquire VAP and,
accordingly, did not get apportioned
protective “immortal time.” This time-
dependent bias is apparent during the first
2 weeks and gradually attenuates, being
practically nonexistent at 4 weeks (after which
only a few patients acquire VAP) (Figure 2A).
Approach 2 accounts for the time-
dependent nature of VAP onset by
comparing the original population with
patients who had remained VAP-free
by each consecutive time wave, which
eliminates immortal time bias (8). However,
it fails to fully respect the temporal ordering
of events because deceased patients receive
weights that incorporate information on
future events while ignoring information on
past events (for more details, see the online
supplement). The (modest) protective
negative “bump” during the first 10 days
(Figure 2B) may partly be explained by
this residual, more subtle form of time-
dependent bias. In contrast to earlier reports
(8), results obtained by this approach can
therefore not be causally interpreted, even
given sufficient confounding adjustment (9).
Approach 3 (Figure 2C), a less familiar
MSM-based approach closer in spirit to











Approach 1: CR analysis







Approach 2: CR analysis that
 treats VAP as a competing event
C
Approach 3: CR analysis that
 treats VAP as a censoring event
D
Approach 4: CR analysis adjusted
 for time−dependent confounding























Day since ICU admission
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Day since ICU admission
0 30 60
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0 30 60
Figure 2. Results of the four different CR analysis approaches for estimating the time-dependent population-attributable fraction (PAF) of intensive care unit
(ICU) mortality due to ventilator-associated pneumonia (VAP): a CR analysis restricted to VAP-free patients (approach 1; panel A), a CR analysis that treats
VAP as a competing event (approach 2; panel B), a CR analysis that treats VAP as a censoring event (approach 3; panel C), and a CR analysis adjusted for
time-dependent confounding (approach 4; panel D). Upper panels: observed cumulative incidence of ICU mortality (black curves) and estimated
counterfactual VAP-free cumulative incidence of ICU mortality (gray curves). Lower panels: estimated PAF of ICU death due to VAP (solid lines) and 95%
pointwise confidence intervals (shaded areas). CR=competing risk.
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data (10, 20, 33–35), fully eliminates all
forms of time-dependent bias because it
apportions weights that do not incorporate
information on future events and exploit
additional available information on past
events. The residual time-dependent bias
produced by approach 2, which can be
readily quantified by comparing the results
of approaches 2 and 3, is clearest within the
first days and weeks. Although it seems to
become negligible toward the end of follow-
up, bias may remain more pronounced in
settings with different temporal dynamics
of the considered events (9). In general,
residual time-dependent bias is expected
to be relatively small whenever exposure
prevalence is low, as in our study (although
see reference 19 for an example with a higher
exposure prevalence).
Finally, approach 4 assigns weights to
deceased patients that not only depend on
their time of death (as in approach 3), but
also on their individual characteristics
and (evolution of) disease severity. As
in approach 3, this approach compares
the original population with the same
population in a hypothetical world in
which VAP is eradicated, but it no longer
naively assumes that on any given day,
incident VAP cases are exchangeable with
hospitalized VAP-free patients. Comparing
results from the third and the last
(benchmark) analysis (Figures 2C and 2D)
indicates that once measured imbalances
over time are adjusted for, the estimated
counterfactual cumulative incidence curve
more closely matches the observed
cumulative incidence curve or, in other
words, that a considerable share of patients
who die with VAP do not die of VAP. In line
with recent findings (9), adjusting only for
baseline confounders produces results that are
almost identical to an unadjusted analysis
(approach 3) (see Figure E5 in the online
supplement). This suggests that, in acute
settings such as the ICU, imbalances at
baseline may often be negligible but accrue
over time. Although observational studies
based on MSMs have similarly indicated a
relatively modest excess risk of ICU death due
to VAP (9, 31, 32), these estimates may
still have been upwardly biased because of
failure to adjust for time-dependent
confounding.
Limitations
Although our final estimates may be
considered more reliable than those obtained
by other approaches, they are also prone to
bias. First, residual confounding bias cannot
be ruled out because certain confounders may
have been either unknown or simply missing
from available databases, or because of
potential misspecification of the Cox model
fitted to calculate IP weights. However, these
concerns may be rather limited compared
with other studies, as, in accordance with
Bekaert and colleagues (13), our analysis
adjusted for a much richer set of available
time-varying confounders. Second,
measurement error in VAP diagnosis as well
as timing of its onset (because of an
incubation effect) may have affected our
analysis. Missed VAP cases may have resulted
in underestimation of VAP incidence and,
consequently, also the VAP-attributable
fraction. Underestimation may also be likely
in case of ascertainment bias (e.g., when
missed VAP cases would be more common
among severely ill patients with a treatment
limitation decision; see online supplement for
details on how we attempted to tackle this).
Finally, as pointed out elsewhere (13), we
emphasize that our analysis estimated the
fraction of ICU mortality attributable to
diagnosed and treated VAP that could not be
prevented by current state-of-the-art
prevention efforts. As such, we caution
against interpreting our findings as an
indication to minimize the importance of
prevention measures (as current measures
may likely have prevented VAP and
considerably shortened hospitalization in
many patients), accurate diagnosis, or
adequate treatment, because these are
inherently captured by our estimates.
Table 2. Comparison of estimates of the PAF of ICU death due to VAP as obtained by four different competing risk analyses
10 Days since ICU
Admission
30 Days since ICU
Admission
60 Days since ICU
Admission
Patients with VAP infection, n (%) 160 (5.9) 208 (7.6) 210 (7.7)
VAP-free ICU deaths, n (%) 316 (11.6) 452 (16.6) 471 (17.3)
ICU deaths, n (%) 340 (12.5) 513 (18.9) 540 (19.9)
Approach 1: competing risk analysis restricted to patients who remain VAP-free until end of follow-up
Estimated deaths had VAP been eradicated, n (%)* 342.4 (12.6) 489.8 (18.0) 510.4 (18.8)
Estimated PAF, % (95% CI) 20.7 (23.6 to 0.2) 4.5 (1.8 to 7.4) 5.5 (2.9 to 8.2)
Approach 2: competing risk analysis that treats VAP acquisition as a competing event
Estimated deaths had VAP been eradicated, n (%)* 335.8 (12.3) 489.4 (18.0) 510.4 (18.8)
Estimated PAF, % (95% CI) 1.3 (21.5 to 3.7) 4.6 (1.9 to 7.4) 5.5 (2.9 to 8.2)
Approach 3: competing risk analysis that treats VAP acquisition as a censoring event
Estimated deaths had VAP been eradicated, n (%)* 331.6 (12.2) 488.6 (18.0) 512.2 (18.8)
Estimated PAF, % (95% CI) 2.5 (20.3 to 5.1) 4.8 (2.0 to 7.7) 5.2 (2.6 to 7.8)
Approach 4: competing risk analysis that adjusts for time-dependent confounding by IP weighting
Estimated deaths had VAP been eradicated, n (%)* 333.8 (12.3) 496.2 (18.2) 520.1 (19.1)
Estimated PAF, % (95% CI) 1.8 (21.1 to 4.8) 3.3 (0.2 to 6.3) 3.7 (0.8 to 6.6)
Definition of abbreviations: CI = confidence interval; ICU= intensive care unit; IP = inverse probability; PAF=population-attributable fraction; VAP= ventilator-
associated pneumonia.
*The counterfactual risk of ICU death by Day t had VAP been prevented for all is estimated by weighing each VAP-free ICU death before or at Day t by a factor
that captures the degree of depletion of patients with VAP infection by the end of study follow-up (approach 1), by Day t (approach 2), by the corresponding
time of ICU death (approach 3), or with a similar observed covariate history by the corresponding time of ICU death (approach 4). See the online supplement
for more details.
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Conclusions
In conclusion, this study replicates
earlier findings of limited ICU mortality
attributable to treated VAP given
current state-of-the-art VAP prevention
measures (13) in an independent cohort using
the same causal modeling techniques for
estimation. In addition, it provides a
compelling illustration that 1) failure to
(properly) account for the time-dependent
nature of events may misleadingly indicate
survival advantages of infected patients
shortly after ICU admission and 2) failure to
account for the time-dependent nature of
confounding leads to systematic overestimation
of the PAF, mostly toward end of follow-up.n
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